Gsk (GSK) Long-Term Investments (2009 - 2026)

Gsk's Long-Term Investments history runs 18 years deep, the most recent figure standing at $135.5 million for Q2 2026.

• In Q2 2026, Long-Term Investments rose 15.43% year-over-year to $135.5 million; the TTM figure through Jun 2026 stood at $135.5 million (up 15.43% YoY), while the FY2025 annual figure was $117.3 million, down 4.37% from the prior year.
• Long-Term Investments for Q2 2026 stood at $135.5 million, up from $133.5 million in the prior quarter.
• The five-year high for Long-Term Investments was $18.5 billion in Q4 2022, with the low at $58.4 million in Q1 2024.
• The 5-year median for Long-Term Investments is $114.4 million (2022), against an average of $1.2 billion.
• The sharpest annual moves came in 2022 and 2023: Long-Term Investments soared 543.95% in 2022, then slumped 92.35% in 2023.
• Gsk's Long-Term Investments stood at $18.5 billion in 2022, then plunged by 92.35% to $1.4 billion in 2023, then plunged by 91.27% to $123.2 million in 2024, then slipped by 3.92% to $118.4 million in 2025, then advanced by 14.47% to $135.5 million in 2026.
• Business Quant data shows GSK's Long-Term Investments at $135.5 million in Q2 2026, $133.5 million in Q1 2026, and $118.4 million in Q4 2025.